Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
about
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedsideLipids, blood pressure and kidney update 2015PCSK9 inhibition: the way forward in the treatment of dyslipidemiaDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersNew Era of Lipid-Lowering DrugsPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraTherapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemiaPCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBA Highly Durable RNAi Therapeutic Inhibitor of PCSK9.Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials.Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapyHDL is redundant for adrenal steroidogenesis in LDLR knockout mice with a human-like lipoprotein profile.Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.Calorically restricted diets decrease PCSK9 in overweight adolescents.Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.Evolocumab: A Review in Hyperlipidemia.Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.Familial Hypercholesterolaemia in the Era of Genetic Testing.Statins and Their Effect on PCSK9-Impact and Clinical Relevance.Managing the lipid profile of coronary heart disease patients.PCSK9 inhibition: the dawn of a new age in cholesterol lowering?Challenges with Evidence-Based Management of Stable Ischemic Heart Disease.Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapyWhole-Exomes Sequencing Delineates Gene Variants Profile in a Young Saudi Male with Familial Hypercholesterolemia: Case Report.The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Trial: Where to Now?Prevention of cardiovascular diseases.PCSK9 signaling pathways and their potential importance in clinical practice.Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials.Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
P2860
Q26741449-F920CA0A-0828-4A77-9DB7-80A0BA6BA6C6Q26771550-684FEC3D-8B20-429A-B24A-9EEFDEDC642FQ26784482-77EC79FA-CDCC-497B-AD23-867B4960406BQ28070296-E3622A40-6BED-41E4-AA99-237A4951B66AQ28072298-E07FC7D1-8A85-4833-984E-B0C15FA03C8BQ28073656-7984C114-5415-4882-A917-3E638B4E008BQ33670893-20C4CB61-9777-464E-8214-D109576299FFQ33728343-3740DA6F-1234-4722-A840-149F25474C6BQ33904455-739938F7-AE41-41CF-9945-1BEBA189DB2BQ33908782-9102FFEC-F9E7-4C5E-9259-3A062842CC7FQ34047773-83E4B9B2-207D-4E17-9FA9-36597203BD3CQ36091331-2CC071D3-D3D6-4C20-8905-C4E4FD467DE4Q36107244-BDE32982-8033-42C4-B27A-D8C3DF42A2D6Q36268257-C843060F-E5CD-4D4F-B17A-4B24C14B2F0BQ36679305-AB8CE65F-7EE1-4682-9EF4-11E3AE4C5ED3Q36731763-0D80A226-28D4-49A9-B380-69D9B581C71CQ37602310-5C2BFE69-6B28-4F12-913A-2472E618FDB7Q38380440-17FE599E-2E2C-40E2-9AEF-2AB432E1A32CQ38596398-C9A774AE-FECE-4245-AE95-662229A87EF4Q38657213-B0F38074-AC34-490E-AC7F-47E039029073Q38661399-CC2402E4-98C9-49DC-A751-8503698DC6FAQ38664321-C9E77E6C-59E0-4916-9E5B-3660ACCC4293Q38784635-9A220D89-A356-44DA-BAC6-8BE0F0D6F38FQ38868416-CC5365D5-8F79-4896-89BF-BCA84AC40AC6Q38934909-BC31EEE6-22DE-43BB-9668-55C33236B43CQ39057046-BB905E62-7482-44EF-AC61-92BAA1D7A12BQ39129336-AE97F150-AA7C-48FB-9946-7CB2873CF1B2Q39148923-EEF27EDE-7DD7-40DD-8035-A36D951C7FCFQ39237132-B196BAFC-881D-4020-B7CF-9DB22B251F89Q39324079-7DBD2D5A-9A42-4447-8288-8ACFAFC7FBD6Q39427680-E73449C7-7C04-4FD2-97C4-259F84897EB5Q40100018-D6874935-61DF-4027-B48A-28340DF6BC82Q40984110-E73AC556-0461-422A-B37D-86AC726AE74FQ41177170-129D6A40-FFBC-4E6A-B6D6-D943004FE8BAQ43056005-D62A2F24-587B-4DD8-80B5-13FF77622928Q43226733-0F1ED9DD-D509-41EC-912E-643D0CF22528Q47134612-CBAB2E89-703A-45A0-8D62-E8EC17DCDE66Q47136279-61AA66B0-F96C-4CB3-A695-5904B5625B05Q47139916-9A281446-978E-424F-ACBB-E9C230C5836EQ47279052-E54EAD07-7A67-4AAC-9A77-DED6716D90B7
P2860
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety and efficacy of anti-PC ...... randomized, controlled trials
@ast
Safety and efficacy of anti-PC ...... randomized, controlled trials
@en
type
label
Safety and efficacy of anti-PC ...... randomized, controlled trials
@ast
Safety and efficacy of anti-PC ...... randomized, controlled trials
@en
prefLabel
Safety and efficacy of anti-PC ...... randomized, controlled trials
@ast
Safety and efficacy of anti-PC ...... randomized, controlled trials
@en
P2093
P2860
P1433
P1476
Safety and efficacy of anti-PC ...... randomized, controlled trials
@en
P2093
Guan-Nan Li
Jian-Zhou Chen
Li-Na Kang
Qin-Hua Chen
Qing-Qing Zhu
Xin-Lin Zhang
P2860
P2888
P356
10.1186/S12916-015-0358-8
P407
P50
P577
2015-06-23T00:00:00Z